| Literature DB >> 26601122 |
Thomas Aherne1, Seamus McHugh1, Elrasheid A Kheirelseid1, Michael J Lee2, Noel McCaffrey3, Daragh Moneley1, Austin L Leahy1, Peter Naughton1.
Abstract
Peripheral arterial disease (PAD) is associated with considerable morbidity and mortality. Consensus rightly demands the incorporation of supervised exercise training (SET) into PAD treatment protocols. However, the exact role of SET particularly its relationship with intervention requires further clarification. While supervised exercise is undoubtedly an excellent tool in the conservative management of mild PAD its use in more advanced disease as an adjunct to open or endovascular intervention is not clearly defined. Indeed its use in isolation in this cohort is incompletely reported. The aim of this review is to clarify the exact role of SET in the management of symptomatic PAD and in particular to assess its role in comparison with or as an adjunct to invasive intervention. A systematic literature search revealed a total 11 randomised studies inclusive of 969 patients. All studies compared SET and intervention with monotherapy. Study results suggest that exercise is a complication-free treatment. Furthermore, it appears to offer significant improvements in patients walk distances with a combination of both SET and intervention offering a superior walking outcome to monotherapy in those requiring invasive measures.Entities:
Year: 2015 PMID: 26601122 PMCID: PMC4639651 DOI: 10.1155/2015/960402
Source DB: PubMed Journal: Surg Res Pract ISSN: 2356-6124
Treatment groups and disease level.
| Study | Patient number | Intervention | Disease level | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| EVR | SET | EVR + SET | INV | Surgery | Surgery + SET | Fem-pop | Aortoiliac | Multilevel | ||
|
Lundgren et al. [ | 75 | 25 | 25 | 25 | Not recorded | |||||
| Creasy et al./Perkins et al. [ | 56 | 30 | 26 | 28 | 25 | 0 | ||||
| Gelin et al. [ | 164 | 88 | 66 | Not recorded | ||||||
| Hobbs et al. [ | 23 | 9 | 7 | 23 | 0 | 0 | ||||
| Badger et al. [ | 14 | 6 | 8 | 14 | 0 | 0 | ||||
| Greenhalgh et al. [ | 127 | 60 | 67 | 93 | 94 | |||||
| Kruidenier et al. [ | 70 | 35 | 35 | 5 | 60 | 5 | ||||
| Mazari et al. [ | 178 | 60 | 60 | 58 | Not recorded | |||||
| Spronk et al./Fakhry et al. [ | 151 | 76 | 75 | 44 | 106 | — | ||||
| Murphy et al. [ | 111 | 46 | 43 | 0 | 111 | 0 | ||||
| Bø et al. [ | 50 | 21 | 29 | 25 | 25 | 0 | ||||
EVR: endovascular revascularization; SET: supervised exercise therapy; INV: invasive management; Fem-pop: femoropopliteal.
Figure 1Flow diagram depicting study identification.
Assessment of bias.
| Lundgren et al. [ | Random sequence generation | Randomised but not described | Unclear risk of bias |
| Allocation concealment | Randomised but not described | Unclear risk of bias | |
| Blinding of participants and personnel | Blinding not possible | Not assessed | |
| Incomplete outcome data | Follow-up data in each group incomplete | Moderate risk of bias | |
| Selective reporting | Clear outcomes | Low risk of bias | |
| Other sources of bias | None | Low risk of bias | |
|
| |||
| Creasy et al./Perkins et al. [ | Random sequence generation | Randomised but not described | Unclear risk of bias |
| Allocation concealment | Randomised but not described | Unclear risk of bias | |
| Blinding of participants and personnel | Blinding not possible | Not assessed | |
| Incomplete outcome data | No loss to follow-up reported | Low risk of bias | |
| Selective reporting | Clear outcomes | Low risk of bias | |
| Other sources of bias | None | Low risk of bias | |
|
| |||
| Gelin et al. [ | Random sequence generation | Randomised via computer based algorithm | Low risk of bias |
| Allocation concealment | Randomised via computer based system | Low risk of bias | |
| Blinding of participants and personnel | Blinding not possible | Not assessed | |
| Incomplete outcome data | Some loss to follow-up | Moderate risk of bias | |
| Selective reporting | Clear outcomes | Low risk of bias | |
| Other sources of bias | None | Low risk of bias | |
|
| |||
| Hobbs et al. [ | Random sequence generation | Randomised with 2 × 2 factorial design | Low risk of bias |
| Allocation concealment | Computer generated randomisation | Low risk of bias | |
| Blinding of participants and personnel | Blinding not possible | Not assessed | |
| Incomplete outcome data | Four withdrawals | Low risk of bias | |
| Selective reporting | Clear outcomes | Low risk of bias | |
| Other sources of bias | None | Low risk of bias | |
|
| |||
| Badger et al. [ | Random sequence generation | Randomised but not described | Unclear risk of bias |
| Allocation concealment | Randomised but not described | Unclear risk of bias | |
| Blinding of participants and personnel | Blinding not possible | Not assessed | |
| Incomplete outcome data | All patients lost to 6-month follow-up | High risk of bias | |
| Selective reporting | Clear outcomes | Low risk of bias | |
| Other sources of bias | None | Low risk of bias | |
|
| |||
| Greenhalgh et al. [ | Random sequence generation | Detailed description of Stata generated randomisation | Low risk of bias |
| Allocation concealment | Computer generated randomisation | Low risk of bias | |
| Blinding of participants and personnel | Blinding not possible | Not assessed | |
| Incomplete outcome data | Moderate loss to follow-up | Moderate risk of bias | |
| Selective reporting | Clear outcomes | Low risk of bias | |
| Other sources of bias | None | Low risk of bias | |
|
| |||
| Kruidenier et al. [ | Random sequence generation | Computer generated block randomisation | Low risk of bias |
| Allocation concealment | Computer generated block randomisation | Low risk of bias | |
| Blinding of participants and personnel | No blinding | High risk of bias | |
| Incomplete outcome data | Moderate losses to follow-up | Moderate risk of bias | |
| Selective reporting | Clear outcomes | Low risk of bias | |
| Other sources of bias | None | Low risk of bias | |
|
| |||
| Mazari et al. [ | Random sequence generation | Sealed envelope used to randomise | Low risk of bias |
| Allocation concealment | Sealed envelope used to randomise | Low risk of bias | |
| Blinding of participants and personnel | Blinding not described | Unclear risk of bias | |
| Incomplete outcome data | Moderate loss to follow-up | Moderate risk of bias | |
| Selective reporting | Clear outcomes | Low risk of bias | |
| Other sources of bias | None | Low risk of bias | |
|
| |||
| Spronk et al./Fakhry et al. [ | Random sequence generation | Computer generated block randomisation | Low risk of bias |
| Allocation concealment | Computer generated block randomisation | Low risk of bias | |
| Blinding of participants and personnel | Blinding not possible | Not assessed | |
| Incomplete outcome data | Prolonged study with some loss to follow-up | Moderate risk of bias | |
| Selective reporting | Clear outcomes | Low risk of bias | |
| Other sources of bias | None | Low risk of bias | |
|
| |||
| Murphy et al. [ | Random sequence generation | Web based randomisation | Low risk of bias |
| Allocation concealment | Web based randomisation | Low risk of bias | |
| Blinding of participants and personnel | Observers blinded | Low risk of bias | |
| Incomplete outcome data | Prolonged study with some loss to follow-up | Moderate risk of bias | |
| Selective reporting | Clear outcomes | Low risk of bias | |
| Other sources of bias | None | Low risk of bias | |
|
| |||
| Bø et al. [ | Random sequence generation | Computer based randomisation | Low risk of bias |
| Allocation concealment | Computer based randomisation | Low risk of bias | |
| Blinding of participants and personnel | Observers blinded | Low risk of bias | |
| Incomplete outcome data | No loss to follow-up | Low risk of bias | |
| Selective reporting | Clear outcomes | Low risk of bias | |
| Other sources of bias | None | Low risk of bias | |
Supervised exercise versus endovascular revascularization.
| Study | Follow-up | ABPI |
| MWD |
| ICD |
| |||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Endpoint | Baseline | Endpoint | Baseline | Endpoint | |||||
| Hobbs et al. [ | ||||||||||
| EVR | 6 months | 0.69 | 0.93 | 0.013† | 185 | 698 | 0.008† | 84 | 698 | 0.011† |
| SET | 0.66 | 0.70 | 0.46† | 111 | 124 | 0.35† | 59 | 92 | 0.074† | |
| Mazari et al. [ | ||||||||||
| EVR | 12 months | 0.71 | 0.90 | 77 | 146 | 31 | 75 | |||
| SET | 0.72 | 0.84 | 0.093 | 83 | 215 | 0.2 | 42 | 97 | 0.48 | |
| Spronk et al./Fakhry et al. [ | ||||||||||
| EVR | 7 years | 0.63 | 0.84 | 174 | 1248 | 82 | 1022 | |||
| SET | 0.62 | 0.82 | 0.8 | 186 | 1168 | 0.48 | 104 | 804 | 0.15 | |
| Murphy et al. [ | ||||||||||
| EVR | 18 months | 0.7 | 0.7 | 5.2 min | 8.4 min | 1.8 min | 4.8 min | |||
| SET | 0.6 | 0.6 | <0.001 | 5.6 min | 10.6 min | 0.16 | 1.8 min | 5.1 min | 0.77 | |
ABPI: ankle brachial pressure index; MWD: maximal walk distance; ICD: intermittent claudication distance; EVR: endovascular revascularization; SET: supervised exercise therapy. Distances in metres unless otherwise stated. min represents time in minutes, claudication onset time/maximal walk time. P value represents statistical comparison of interventions except in Hobbs et al. [21] where † represents change in measurement over study period.
Supervised exercise plus invasive measures (open surgery or EVR) versus monotherapy.
| Study | Follow-up | ABPI |
| MWD |
| ICD |
| |||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Endpoint | Baseline | Endpoint | Baseline | Endpoint | |||||
| Lundgren et al. [ | ||||||||||
| Surgery | 13 months | 0.55 | — | 209 | 570 | 85 | 405 | |||
| SET | 0.59 | — | 180 | 654 | 70 | 559 | ||||
| Surgery + SET | 0.59 | — | <0.001 | 183 | 459 | 0.05 | 67 | 187 | 0.006 | |
| Badger et al. [ | ||||||||||
| Surgery | 6 months | — | — | — | — | — | — | — | ||
| Surgery + SET | — | — | 0.02 | — | — | 0.001 | — | — | — | |
| Greenhalgh et al. [ | ||||||||||
| SET | 24 months | 0.66 | 0.74 | 126 | 168 | — | — | — | ||
| EVR + SET | 0.68 | 0.90 | 0.02 | 114 | 354 | 0.05 | — | — | — | |
| Greenhalgh et al. [ | ||||||||||
| SET | 24 months | 0.69 | 0.72 | 126 | 155 | — | — | — | ||
| EVR + SET | 0.66 | 0.83 | 0.01 | 133 | 245 | 0.4 | — | — | — | |
| Kruidenier et al. [ | ||||||||||
| EVR | 6 months | 0.71 | 0.93 | 282 | 685 | 343 | 547 | |||
| EVR + SET | 0.69 | 0.88 | 0.755 | 186 | 956 | 0.001 | 293 | 842 | 0.001 | |
| Mazari et al. [ | ||||||||||
| EVR | 12 months | 0.71 | 0.9 | 77 | 146 | 31 | 75 | |||
| SET | 0.72 | 0.84 | 83 | 215 | 42 | 97 | ||||
| EVR + SET | 0.64 | 0.92 | 0.93 | 85 | 187 | 0.259 | 43 | 99 | 0.484 | |
| Bø et al. [ | ||||||||||
| EVR | 3 months | — | — | 213 | 427 | 94 | 267 | |||
| EVR + SET | — | — | <0.001 | 385 | 584 | NS | 101 | 456 | NS | |
ABPI: ankle brachial pressure index; MWD: maximal walk distance; ICD: intermittent claudication distance; EVR: endovascular revascularization; SET: supervised exercise therapy. Distances in metres unless otherwise stated. ∗ represents significant improvement favouring combined treatment. P value represents statistical comparison of interventions. — represents nonreported figures.
Invasive (EVR or surgery) management versus supervised exercise.
| Study | Follow-up | ABPI |
| MWD |
| ICD |
| |||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Endpoint | Baseline | Endpoint | Baseline | Endpoint | |||||
| Gelin et al. [ | ||||||||||
| INV | 12 months | 0.55 | 0.71 | <0.01† | 274 | 344 | <0.01† | — | — | — |
| SET | 0.56 | 0.54 | — | 258 | 247 | — | — | — | — | |
ABPI: ankle brachial pressure index; MWD: maximal walk distance; ICD: intermittent claudication distance; EVR: endovascular revascularization; SET: supervised exercise therapy. Distances in metres unless otherwise stated. P value represents statistical comparison of interventions. † represents change in measurement over study period.
Figure 2Management of intermittent claudication incorporating supervised exercise therapy.